Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women

Menopause

Volumn 9, Issue 5, 2002, Pages 360-366

  Sanada, Mitsuhiro ^a   Higashi, Yukihito ^a   Nakagawa, Keigo ^a   Tsuda, Mikio ^a   Kodama, Ichiro ^a   Nagai, Nobutaka ^a   Chayama, Kazuaki ^a   Ohama, Koso ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelial function; Estrogen; Medroxyprogesterone; Nitric oxide; Vasodilation

Indexed keywords

CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NITRATE; NITRITE; PLACEBO; RENIN; ESTROGEN; PROGESTERONE DERIVATIVE;

ADULT; ARTERY ENDOTHELIUM; ARTERY RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; LIPOPROTEIN BLOOD LEVEL; MENOPAUSAL SYNDROME; PLASMA RENIN ACTIVITY; PLETHYSMOGRAPHY; SIDE EFFECT; TIME SERIES ANALYSIS; BLOOD; BLOOD FLOW VELOCITY; DRUG COMBINATION; ESTROGEN THERAPY; FOREARM; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE; VASCULAR ENDOTHELIUM;

BLOOD FLOW VELOCITY; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FOREARM; HUMANS; HYPERCHOLESTEROLEMIA; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS;

EID: 0036728869     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200209000-00009     Document Type: Article

References (37)

1. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-762.
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
3. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
5. Grady D, Rubin SM, Petitti DB, Fox CS. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
6. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-941.
7. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-791.
8. Collins P, Rosano GM, Sarrel PM, et al. 17 beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
10. Tan E, Gurjar MV, Sharma RV, Bhalla RC. Estrogen receptor-alpha gene transfer into bovine aortic endothelial cells induces eNOS gene expression and inhibits cell migration. Cardiovasc Res 1999;43:788-797.
11. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997;3:324-327.
12. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.
13. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997;127:501-508.
14. Investigating committee of guideline for diagnosis and treatment of hyperlipidemias. J Jpn Atheroscler Soc 1997;25:1-34.
15. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27.
16. Higashi Y, Sasaki S, Kurisu N, et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation 1999;100:1194-1202.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. 15N nitrate in biological fluids. Anal Biochem 1982;126:131-138.
19. Celermajer DS, Sorensen K, Gooch V, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;40:1111-1115.
20. Mastumoto A, Hirata Y, Momomura S, et al. Increased nitric oxide production during exercise. Lancet 1994;343:849-850.
21. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.
22. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-1109.
23. Sanada M, Nakagawa H, Kodama I, Sakashita T, Ohama K. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Metabolism 2000;49:784-789.
24. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1994;334:160-162.
25. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
26. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
27. Sanada M, Higashi Y, Sasaki S, et al. Relationship between angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol 2001;37:1529-1535.
28. Sanada M, Higashi Y, Nakagawa K, et al. Estrogen replacement therapy in postmenopausal women augments reactive hyperemia in the forearm by reducing angiotensin converting enzyme activity. Atherosclerosis 2001;158:391-397.
29. Proudler AJ, Ahmed AH, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995;346:89-90.
30. Sumino H, Ichikawa S, Kanda T, et al. Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. Am J Hypertens 1999;12:1044-1047.
31. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
32. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994;23:439-449.
33. Kawano H, Motoyama T, Hirai N, et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. Am J Cardiol 2001;87:238-240.
34. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998;98:1158-1163.
35. Koh, KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestogen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-1966.
36. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and risk of stroke: follow-up of a population based cohort in Sweden. Arch Intern Med 1993;153:1201-1209.
37. Sanada M, Higashi Y, Nakagawa K, et al. Oral estrogen replacement therapy increases forearm reactive hyperemia accompanied by increases in serum levels of nitric oxide in postmenopausal women. Gynecol Endocrinol 2001;15:150-157.